Guests/Speakers
Wendy Brooks – Lung cancer patient, LCFA Speakers Bureau member
Dr. Ashish Saxena – MD, PhD, Thoracic Medical Oncology, Weill Cornell Medicine
A Frightening Diagnosis—and Reasons for Hope
When Wendy Brooks was diagnosed with small cell lung cancer (SCLC) three years ago, fear was the first emotion she felt. It’s a reaction Dr. Ashish Saxena of Weill Cornell Medicine hears often—and one he meets with reassurance: patients aren’t walking this road alone, and the science behind small cell lung cancer treatment is moving faster than ever.
“There’s been this really big explosion of new treatments for small cell lung cancer, which is really exciting,” – Dr. Saxena
Why Small Cell Lung Cancer Is Different—And What’s Changing
Small cell lung cancer is known for moving quickly, but Dr. Saxena emphasizes one important fact: SCLC is initially very sensitive to chemotherapy and radiation, allowing oncologists to gain control of the disease relatively quickly. What’s new—and game-changing—is what comes next.
Today, immunotherapy is part of the standard of care for both early- and later-stage small cell lung cancer. Checkpoint inhibitors help the immune system better recognize and attack cancer cells. And newer therapies are pushing the boundaries even further, including:
- Bispecific T-cell engagers that physically bring immune cells to cancer cells
- Anti-angiogenic targeted therapies (like VEGF inhibitors)
- Small molecule inhibitors designed for specific subtypes of SCLC
- Combination therapies pairing checkpoint inhibitors with other targeted agents
“I have patients living so much longer,” Dr. Saxena said. “And not only just being alive, but completely fine and just living their lives.”
Clinical Trials: A Lifeline, Not a Last Resort
One of the most important takeaways from this conversation is a fundamental reframing of clinical trials. Many patients hear “clinical trial” and think “experimental” or “last resort.” Dr. Saxena wants patients to understand the truth.
“What we call standard therapies today, for the most part, started out as a clinical trial,” he explained. “Enrolling in a clinical study, you have the opportunity of getting a future treatment—tomorrow’s treatment—right now.”
Key facts about clinical trials in small cell lung cancer:
- Most trial drugs have already been studied in many patients before reaching you
- Many trials add an investigational drug to the standard of care
- Patients on trials are monitored more closely with frequent scans, blood work, and check-ins
- Trials are often available at the start of treatment—not just after other options fail
Wendy shared her own experience as a clinical trial participant:
“I actually get better than the standard of care. I receive more frequent testing. I see my oncologist more often. My scans are more frequent. That gives me a sense of security.”
Why Timing Matters: Ask About Trials Before You Start Treatment
Dr. Saxena had a critical message for newly diagnosed patients: ask about clinical trials at your very first oncology visit.
“There are some studies that are part of initial therapy where, if you start a therapy, you then no longer qualify to go onto the trial,” he warned. Asking upfront ensures you don’t miss opportunities that may be unavailable later.
Biomarker Testing in Small Cell Lung Cancer
While biomarker testing is a cornerstone of non-small cell lung cancer treatment, its role in SCLC is still evolving. Currently, standard SCLC therapies aren’t always guided by biomarkers, but that’s changing rapidly.
“We would love—like in non-small cell lung cancer—for small cell to say, ‘Oh, you have this biomarker, hence this drug will work better for you,'” Dr. Saxena said. Patients should ask whether biomarker testing could open the door to a clinical trial or inform future treatment decisions.
Questions Every Newly Diagnosed Patient Should Ask
Dr. Saxena recommends starting with these questions:
- What is the standard treatment, and how is it given?
- How does it work, and what are the side effects?
- What clinical trials are available here—or in my area?
- Could biomarker testing be helpful in my case?
- What is the plan if my first treatment stops working?
Managing Side Effects and Protecting Quality of Life
Dr. Saxena urged patients never to hold back side effect concerns out of fear of “complaining.”
“There’s no reason to be afraid to tell the doctor how you’re feeling,” he said. “Sometimes patients think that if they complain, the doctor will say, ‘Well, then forget it, you’re not going to get this treatment anymore.’ That’s generally not the case.”
Instead, side effects can often be managed with:
- Palliative and supportive care services
- Nutrition counseling
- Physical therapy and exercise
- Dose adjustments or symptom-targeted medications
A Message of Hope
For anyone newly diagnosed and feeling overwhelmed, Dr. Saxena’s message is clear: stay hopeful.
“We’ve come a really long way in not that long a period of time. It’s kind of a train that’s going in the right direction really fast, with a lot of new information and studies and drugs coming up.”
As Wendy added: “You’re not a guinea pig. It is a lifeline. We are getting that science of tomorrow into our bodies today.”
